Dabur India Ltd logo

Dabur India Ltd

DABUR NSE

Dabur is India’s leading FMCG, Ayurvedic and natural health care company with wide network distribution across world. [1]

AI Verdict: HOLD Confidence: 5%

Dabur India trades at a PE of 40.7x with tepid 5% sales CAGR over 3 years and negative stock returns of -9% over the same period. While the brand portfolio and 70.1% dividend payout offer stability, stretched valuations and deteriorating working capital (18.4 to 85.4 days) limit near-term upside.

Key Fundamentals

MidcapPersonal CareConsumer Goods
Market Cap
₹76,348 Cr
Volatility
Moderate
P/E Ratio
39.65
EBITDA
₹2,435 Cr
Return on Equity
17.58%
Debt to Equity
0.11
Book Value
₹64.37
EPS
₹10.6
52W High
₹577
52W Low
₹403.35

Technical Indicators

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 70.1%

Weaknesses

2
  • The company has delivered a poor sales growth of 6.65% over past five years.
  • Working capital days have increased from 18.4 days to 85.4 days

Growth Rate

Revenue Growth
0.61% ↗
Net Income Growth
8.20% ↗
Cash Flow Change
-1.33% ↘
ROE
-11.66% ↗
ROCE
-8.39% ↗
EBITDA Margin (Avg.)
-19.26% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 3d ago
HOLD
Risk medium

Dabur India trades at a PE of 40.7x with tepid 5% sales CAGR over 3 years and negative stock returns of -9% over the same period. While the brand portfolio and 70.1% dividend payout offer stability, stretched valuations and deteriorating working capital (18.4 to 85.4 days) limit near-term upside.

Bull Case 7
  • Healthy dividend payout of 70.1% provides consistent income with a current yield of 1.92%
  • 10-year ROE average of 21% demonstrates long-term capital efficiency and brand strength
  • TTM profit growth of 8% is accelerating versus 3-year CAGR of 4%, signaling margin recovery
  • Market cap of Rs 75,577 Cr reflects large-cap stability with institutional ownership support
  • 43.24% of analysts rate it a Buy (16 out of 37 analysts), indicating reasonable consensus support
  • 5-year compounded sales CAGR of 7% is ahead of the 10-year average of 5%, showing gradual top-line improvement
  • Price-to-book of 6.66x is supported by asset-light FMCG model with strong intangible brand value
Bear Case 8
  • PE of 40.7x is expensive for a company delivering only 5% TTM sales growth, implying a PEG ratio above 5x
  • Stock CAGR of -9% over 3 years indicates sustained value destruction for shareholders
  • Working capital days surged from 18.4 to 85.4 days, signaling cash conversion cycle deterioration
  • 5-year compounded profit CAGR of just 2% indicates prolonged earnings stagnation
  • ROE declining from 21% (10-year) to 17% (last year) shows fading return on equity trajectory
  • 16.22% of analysts rate it a Sell (6 out of 37), a notable bearish minority for a large-cap FMCG name
  • 10-year stock CAGR of only 3% significantly underperforms broader market indices like Nifty 50
  • Poor sales growth of 6.65% over five years in a sector where volume-led growth is critical

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Headwinds 1
  • US FDA import alert Silvassa Jun 12

    US FDA issued import alert for Dabur's Silvassa plant, potentially detaining products at US ports without physical examination. Company claims financial impact is insignificant but regulatory overhang and data integrity concerns persist.

Positives 2
  • Strategic Global Capability Centers Jun 8

    Dabur announced establishment and scaling of Strategic Global Capability Centers including a dedicated Digital Marketing GCC, signaling investment in centralized global operations and digital capabilities.

  • Zero promoter share encumbrance Jun 4

    Promoters held 1.175 billion shares as of March 31, 2026 with zero shares encumbered during FY26, indicating strong promoter confidence and no financial stress at the promoter level.

Neutral 5
  • 51st AGM set for Aug 6 Jun 23

    Dabur India will hold its 51st AGM via video conferencing on August 6, 2026, with book closure from July 20 to July 24.

  • Trading window closed for July Jun 23

    Dabur closed its trading window from July 1 to July 31, 2026 per SEBI insider trading regulations ahead of results season.

  • Sesa Care amalgamation hearing Aug 3 Jun 9

    NCLT New Delhi will hear the Dabur-Sesa Care Private Limited amalgamation scheme petition on August 3, 2026 under Sections 230-232 of Companies Act, 2013.

  • Nuvama London investor conference Jun 2

    Dabur officials attended the Nuvama India Conference 2026 in London on June 8, confirming no unpublished price sensitive information would be shared.

  • Investor group conference Jun 1 May 25

    Dabur scheduled an investor group conference under Regulation 30 on June 1, 2026.

TL;DR: Dabur's recent newsflow is largely routine corporate governance and investor engagement activity. The key risk is the US FDA import alert and data integrity concerns at the Silvassa plant, though the company maintains revenue impact is minimal. On the positive side, the GCC expansion signals long-term digital and operational investment, and zero promoter encumbrance reflects financial stability. The trend is stable with no earnings surprises, but the FDA issue warrants monitoring for escalation.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
2,678
3,130
3,204
3,255
2,815
3,349
3,029
3,355
2,830
3,405
3,191
3,559
3,038
Expenses
2,268
2,526
2,543
2,588
2,348
2,694
2,476
2,673
2,403
2,737
2,603
2,825
2,577
Operating Profit
410
605
661
667
466
655
553
682
427
667
588
734
461
OPM %
15%
19%
21%
20%
17%
20%
18%
20%
15%
20%
18%
21%
15%
Other Income
121
110
117
127
129
129
152
129
141
144
140
126
175
Interest
32
24
28
36
35
33
47
44
39
35
40
31
40
Depreciation
102
97
98
97
107
109
111
109
117
114
115
117
122
PBT
396
593
651
661
453
642
546
658
412
663
573
711
474
Tax %
26%
23%
22%
23%
25%
23%
24%
22%
24%
23%
22%
22%
24%
Net Profit
293
457
507
506
341
494
418
516
313
508
445
554
362
EPS in Rs
1.7
2.62
2.91
2.9
1.97
2.82
2.4
2.95
1.81
2.9
2.55
3.16
2.08
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
7,795
7,780
7,614
7,722
8,515
8,685
9,562
10,889
11,530
12,404
12,563
13,193
Expenses
6,475
6,261
6,102
6,104
6,775
6,892
7,560
8,637
9,367
10,004
10,247
10,743
Operating Profit
1,320
1,518
1,512
1,617
1,740
1,792
2,002
2,252
2,162
2,400
2,316
2,450
OPM %
17%
20%
20%
21%
20%
21%
21%
21%
19%
19%
18%
19%
Other Income
154
217
296
291
222
205
325
308
445
482
551
585
Interest
40
48
54
53
60
50
31
39
78
124
164
145
Depreciation
115
133
143
162
177
220
240
253
311
399
446
469
PBT
1,319
1,554
1,611
1,693
1,725
1,728
2,056
2,269
2,219
2,359
2,258
2,420
Tax %
19%
19%
21%
20%
16%
16%
18%
23%
23%
23%
23%
23%
Net Profit
1,068
1,254
1,280
1,358
1,446
1,448
1,695
1,742
1,701
1,811
1,740
1,869
EPS in Rs
6.07
7.11
7.25
7.69
8.17
8.18
9.58
9.84
9.64
10.4
9.97
10.68
Div. Payout %
33%
32%
31%
81%
34%
37%
50%
53%
54%
53%
80%
77%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
176
176
176
176
177
177
177
177
177
177
177
177
Reserves
3,178
3,995
4,671
5,530
5,455
6,429
7,487
8,205
8,796
9,689
10,623
11,242
Borrowings
734
805
975
938
699
522
509
1,030
1,174
1,365
950
1,287
Other Liabilities
2,019
1,956
1,910
2,058
2,106
2,209
2,661
2,872
3,505
3,885
4,479
4,773
Total Liabilities
6,106
6,932
7,732
8,702
8,437
9,337
10,833
12,284
13,652
15,116
16,230
17,480
Fixed Assets
1,877
1,667
1,958
2,028
1,969
2,253
2,243
2,308
3,579
3,815
3,990
3,939
CWIP
50
45
42
42
64
147
147
168
175
232
169
137
Investments
1,813
2,691
3,240
3,805
3,359
2,800
4,160
6,220
6,265
6,933
7,468
8,947
Other Assets
2,365
2,529
2,492
2,827
3,045
4,137
4,283
3,589
3,633
4,136
4,603
4,456
Total Assets
6,106
6,932
7,732
8,702
8,437
9,337
10,833
12,284
13,652
15,116
16,230
17,480
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
1,047
1,187
1,227
1,092
1,499
1,614
2,115
1,802
1,488
2,013
1,987
2,579
Investing
-876
-730
-807
-541
338
-517
-1,404
-1,273
-583
-971
-448
-1,285
Financing
-417
-374
-339
-577
-1,888
-1,043
-613
-490
-1,035
-1,161
-1,405
-1,236
Net Cash Flow
-245
82
81
-27
-51
54
97
38
-130
-119
133
58
Free Cash Flow
796
998
741
891
1,274
1,213
1,808
1,433
1,003
1,453
1,448
2,180
CFO/OP
97
97
102
88
106
107
122
97
92
104
103
122
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
33
38
31
33
36
34
21
22
27
26
26
20
Inventory Days
136
150
153
169
154
164
178
169
158
149
175
124
Days Payable
153
182
181
190
172
176
197
178
171
186
215
158
Cash Conversion Cycle
16
6
3
13
17
22
3
12
14
-10
-14
-14
Working Capital Days
-17
0
-7
-1
-5
9
-9
-14
-13
-17
-13
85
ROCE %
36%
35%
31%
28%
28%
28%
27%
27%
23%
22%
20%
20%

Shareholding Pattern

As of Mar 2026
Promoters 66.25%
DIIs 18.56%
FIIs 9.98%
Public 4.13%
Others 1.09%
Total 100.01%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters
67.38%
67.36%
67.36%
67.37%
67.38%
67.24%
67.24%
66.24%
66.24%
66.23%
66.23%
66.24%
66.25%
66.24%
66.25%
66.26%
66.27%
66.22%
66.22%
66.23%
66.25%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
15.83%
14.98%
15.04%
13.27%
12.68%
11.85%
10.89%
10.05%
9.98%
DIIs
5.28%
4.61%
3.36%
3.51%
3.78%
3.98%
5.77%
7.61%
8.43%
8.87%
8.61%
10.35%
12.56%
13.56%
13.67%
14.92%
15.69%
16.24%
17.39%
18.38%
18.56%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
5.43%
5.29%
5.28%
5.55%
5.28%
5.18%
4.47%
4.34%
4.32%
4.29%
4.26%
4.28%
4.19%
4.03%
3.92%
4.34%
4.19%
4.44%
4.18%
4.21%
4.13%
Others
21.91%
22.74%
23.99%
23.57%
23.56%
23.61%
22.53%
21.82%
21.00%
20.61%
20.90%
19.13%
1.17%
1.18%
1.12%
1.20%
1.17%
1.25%
1.32%
1.13%
1.09%
No. of Shareholders
2,96,439
3,18,852
3,59,529
4,33,443
4,82,133
4,83,560
4,57,490
4,43,618
4,48,975
4,44,832
4,33,501
4,39,123
4,34,823
4,35,213
4,30,436
5,10,298
5,05,557
5,20,024
4,97,123
4,84,326
4,69,624

Documents

Frequently Asked Questions about Dabur India Ltd

What does Dabur India Ltd do?
Dabur is India’s leading FMCG, Ayurvedic and natural health care company with wide network distribution across world. [1]
Where is Dabur India Ltd (DABUR) listed?
Dabur India Ltd is listed on the Indian stock exchanges. It is listed on NSE: DABUR and BSE: 500096. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Dabur India Ltd belong to?
Dabur India Ltd operates in the Fast Moving Consumer Goods sector within the Personal Products industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Dabur India Ltd?
Dabur India Ltd has a market capitalisation of approximately ₹76348.49 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Dabur India Ltd?
The Price-to-Earnings (PE) ratio of Dabur India Ltd is 39.65. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Dabur India Ltd?
Over the past 52 weeks, Dabur India Ltd has traded between a low of ₹403.35 and a high of ₹577. This range helps investors understand the stock's price volatility and recent trading levels.
Does Dabur India Ltd pay dividends?
Yes, Dabur India Ltd has a dividend yield of 1.95%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Dabur India Ltd?
Dabur India Ltd has a Return on Equity (ROE) of 17.58%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Dabur India Ltd on Tapetide?
On Tapetide, you can view Dabur India Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Dabur is India’s leading FMCG, Ayurvedic and natural health care company with wide network distribution across world. [1]

Website dabur.com
CEO Mr. Mohit Malhotra M.B.A.
Employees 5,341
Listed 1999-04-28
Face Value ₹ 1
Issued Size 1,77,36,90,172

Explore More

More in Fast Moving Consumer Goods → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List